^(131)I-chTNT导向治疗晚期肺癌的临床研究  

The clinical study of I-131 labeled chimeric TNT antibody targeting therapy to 43 patients with advanced lung cancer

作　　者：于力克[1] 徐兆强[2] 陈文萍[1] 李田[1] 蒋长英[3] 

机构地区：[1]南京胸科医院,210029 [2]江苏省人民医院 [3]复旦大学肿瘤医院

出　　处：《中国肺癌杂志》2002年第6期429-431,共3页Chinese Journal of Lung Cancer

摘　　要：目的　分析并评价1 31 I肿瘤细胞核人鼠嵌合单克隆抗体 (1 31 I chTNT)对晚期肺癌的治疗作用 ,选择最佳的给药途径。方法　 43例肺癌患者均经细胞学或病理学证实 ,其中ⅢB期 3 0例 ,Ⅳ期 13例 ;初治 3 2例 ,复治 11例。采用三种途径给药 :(1)静脉组 2 2例 ;(2 )瘤体组 16例 ;(3 )瘤体 +静脉组 5例。1 31 I chTNT剂量均按 2 .96× 10 7Bq kg计算 ,每人 2次 ,间隔 2周。结果　完全缓解 (CR) 2例 (4 .7% ) ,部分缓解 (PR) 11例 (2 5 .6% ) ,总有效率为 3 0 .2 % (13 43 )。其中静脉组有效率为 9.1% ,瘤体组有效率为 5 6.3 % ,有显著性差异 (P <0 .0 1)。主要毒性为骨髓抑制 ,其中Ⅲ度白细胞下降仅占 4.7% (2 43 ) ,Ⅲ度血小板下降占 7.0 % (3 43 ) ,均为静脉组。结论　1 31 I chTNT对晚期肺癌有一定的疗效 。Objective To analysis and evaluate the efficacy of I 131 labeled chimeric TNT antibody ( 131 I chTNT MAb) targeting therapy in advanced lung cancer, and then choose the best way of administration. Methods Forty three patients with advanced lung cancer were treated by 3 different protocols using 131 I chTNT MAb. Their diagnosis was confirmed by histology and there were 30 cases in stage ⅢB and 13 cases in stage Ⅳ, 32 cases were newly diagnosed and 11 cases were retreated. All patients were divided into three groups and treated with different methods: (1)iv infusion (n=22); (2) intratumoral injection (n=16); and (3) combination iv (25% of total dosage) and intratumoral (75%) infusion (n=5). All patients received radiolabeled MAb at a total dosage of 2.96×10 7 Bq/kg on days 1 and 14. Results There were 2 complete response (4.7%), and 11 partial response (25.6%), the total response rate was 30.2% (13/43) in all patients. For those patients receiving iv injection alone, the response rate was 9.1%. For those patients receiving intratumoral injection alone, the response rate was 56.3%. There was significant difference between them (P< 0.01 ). The main toxicity was reversible bone marrow suppression, 2 cases (4.7%) with grade Ⅲ leukopenia and 3 cases (7.0%) grade Ⅲ thrombocytopenia. Conclusion 131 I chTNT has significant therapeutic effects on advanced lung cancer and the intratumoral injection is the best way of administration.

关 键 词：晚期肺癌 ^131I-CHTNT 肺肿瘤 导向治疗 给药方法 

分 类 号：R734.2[医药卫生—肿瘤]